Troy Wilson, PhD, JD
Chairman and Co-Founder
Troy Wilson is a highly-successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and most importantly, patients. He is one of our co-founders and has served as a member of our board of directors since November 2012. Dr. Wilson has served as President and Chief Executive Officer of Kura Oncology, Inc., a public biopharmaceutical company, since August 2014 and as President and CEO of Wellspring Biosciences LLC, a private biopharmaceutical company, and its parent company Araxes Pharma LLC until March 2019.
Dr. Wilson served as the President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc., a private biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceuticals. He has also been a member of the board of directors of Kura Oncology since August 2014, a member of the board of directors of Puma Biotechnology, Inc., a public biopharmaceutical company, since October 2013, and the sole managing member of Araxes Pharma LLC since May 2012, and Executive Chairman of the board of managers of Wellspring Biosciences since July 2012. He holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.
Mr. Boess, who has nearly thirty years of industry experience as a finance executive and board member, brings a wealth of experience in financing, and leading and growing biotechnology companies to Avidity. Mr. Boess also serves on the Board of Directors and is Chair of the Audit Committee at Rocket Pharmaceuticals, a public biopharmaceutical company, and Achilles Therapeutics, a private, London-based biopharmaceutical company. Prior to serving in his board roles, Mr. Boess held executive level positions within the biopharmaceutical industry including Executive Vice President, Corporate Affairs at Kiniksa Pharmaceuticals, Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation (until its acquisition by Alexion Pharmaceuticals) and Chief Financial Officer at Alexion Pharmaceuticals. In addition, Mr. Boess served as Chief Financial Officer, and later, as Vice President of International Operations at Insulet Corporation, Executive Vice President of Finance at Serono Inc., and in several financial executive roles at Novozymes of North America and Novo Nordisk in France, Switzerland and China. During his tenure at Novo Nordisk, he served on Novo Nordisk's Global Finance Board.
Noreen Henig, M.D.
Chief Medical Officer, Kezar Life Sciences
Noreen Henig, M.D. brings over 20 years of clinical and development leadership experience at biopharmaceutical companies, in addition to an extensive background in academic research and medicine. Dr. Henig was appointed Chief Medical Officer of Kezar Life Sciences in May 2020, and prior to that, had served as Chief Medical Officer of Breath Therapeutics since July 2018. Breath Therapeutics was acquired by Zambon SpA in July 2019 for up to 500 Million Euros and is now a Zambon Group Company. Previously, she served as Chief Development Officer of ProQR Therapeutics from 2014 to 2017, where she led preclinical and clinical development. ProQR had a successful cross-over round and IPO as a preclinical company in 2014. Earlier in her drug development career, she spent six years at Gilead Sciences, most recently as the Senior Director, Global Respiratory. Throughout her career, Dr. Henig held several senior academic positions at California Pacific Medical Center and Stanford University School of Medicine. She earned her M.D. with distinction in immunology from Albert Einstein College of Medicine and completed training in internal medicine at the University of California San Francisco, and pulmonary and critical care medicine at the University of Washington.
Edward Kaye, M.D.
Chief Executive Officer and Director, Stoke Therapeutics
Edward Kaye, M.D., has served as CEO and a director of Stoke Therapeutics since October 2017. Dr. Kaye previously served as CEO and a director of Sarepta Therapeutics, where he led the successful push to win FDA approval of Exondys 51, a pioneering drug for Duchenne Muscular Dystrophy. Before taking on the CEO role at Sarepta, he served as the company’s Chief Medical Officer for six years, leading the development of Exondys 51. Earlier in his career, Dr. Kaye spent 10 years at Genzyme Corporation, most recently as Group Vice President of Clinical Development, where he supervised clinical research in programs focused on lysosomal storage disease and genetic neurological disorders. Dr. Kaye currently serves as a member of the boards of directors at Cytokinetics, Inc. and the Massachusetts Biotechnology Council. Prior to entering the biotech industry, Dr. Kaye trained in pediatrics, pediatric neurology and biochemical genetics. He was on the research staff at Massachusetts General Hospital and Tufts University Medical Center and was the chief of biochemical genetics at the Children’s Hospital of Philadelphia. He remains on the pediatric neurology staff at Boston Children’s Hospital. Dr. Kaye earned his B.S. in biology/chemistry from Loyola University and earned his M.D. at the Loyola University Stritch School of Medicine.
Jean Kim is a recognized healthcare investment partner with more than twenty years of biotechnology experience and leadership on Wall Street. Ms. Kim served as a Partner at Deerfield Management Company LP from August 2006 to July 2020 where she provided extensive research and analysis on individual companies operating in the healthcare industry, with a particular focus on rare and orphan diseases. In addition, Ms. Kim incubated and founded a new gene therapy portfolio company at Deerfield Management with a novel incubator company structure focused on rare orphan monogenic diseases. Prior to joining Deerfield, she was a healthcare investment professional for six years with Merrill Lynch Ventures and a Financial Analyst in Merrill Lynch's investment banking department. Ms. Kim received her Bachelor of Arts in English Literature and a Bachelor of Science in Biology from Stanford University. She also holds an MBA from Harvard Business School and a Master of Science degree from the Massachusetts Institute of Technology through the Biomedical Enterprise Program and was a Fulbright Scholar. Ms. Kim serves on the Board of Directors of Amplo Biotechnology, a gene therapy company.
Chief Operations Officer, Cognoa
Eric Mosbrooker has over 20 years of experience in the global commercial operations space with demonstrated leadership and experience in global pricing, marketing, distribution, product launches, and compliance. In addition to his commercial experience, Mr. Mosbrooker has expertise in gene therapy, rare metabolic diseases, additional orphan conditions and oncology. Mr. Mosbrooker currently serves as the Chief Operations Officer for Cognoa, leading the commercial, program management, product, and business operations functions. Prior to joining Cognoa, he was the Chief Commercial Officer at Audentes Therapeutics overseeing the gene therapy business unit. Mr. Mosbrooker also served as the Senior Vice President of the Global Orphan Business Unit at Horizon Pharmaceuticals. He holds a B.S. in Industrial Engineering from the University of Wisconsin – Madison.
VP, Govt. Affairs and Policy, Alexion Pharmaceuticals
Tamar Thompson is a distinguished health policy strategist, government affairs leader and market access executive with a diverse background across multiple healthcare sectors and therapeutic categories including rare disease, immunology, oncology and cardiovascular disease. She has more than twenty years of leadership experience in health care, including a focus on developing strategic and tactical recommendations to ensure optimal reimbursement and market access for rare disease products. Ms. Thompson currently serves as the Vice President, US Government Affairs and Policy for Alexion Pharmaceuticals, Inc. and as the Chair of the Board of Alexion's Charitable Foundation. Prior to joining Alexion, Ms. Thompson served as head, federal executive branch strategy and state government affairs for Bristol-Myers Squibb Company. She also served as a strategic policy advisor and consultant for premiere Washington, DC based firms, including ADVI, Kimbell and Associates and Avalere Health. Ms. Thompson holds an M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress California.
President & Chief Executive Officer
Sarah Boyce brings to Avidity extensive experience in the life sciences industry, where she has built global organizations and brought to patients a number of innovative therapies, including Tegsedi®, Waylivra®, Soliris®, Gleevec® and Tasigna®. She most recently served as President and a member of the board of directors of Akcea Therapeutics, where she led commercialization of the company’s rare disease products. Prior to joining Akcea in April 2018, Ms. Boyce held multiple executive-level roles at leading pharma and biotech companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche.